NCT00005039终止2 期
A Phase II Randomized Trial of Recombinant Fowlpox and Recombinant Vaccinia Virus Expressing PSA in Patients With Adenocarcinoma of the Prostate
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 86
- 试验地点
- 2
- 主要终点
- PSA response
研究概览
简要总结
Randomized phase II trial to determine the effectiveness of vaccine therapy in treating patients who have advanced adenocarcinoma of the prostate (prostate cancer). Vaccines made from a person's prostate cancer cells may make the body build an immune response to kill tumor cells
详细描述
OBJECTIVES:
I. Determine the toxicity and maximum tolerated dose of recombinant fowlpox prostate-specific antigen (PSA) vaccine in patients with advanced adenocarcinoma of the prostate.
II. Determine whether vaccination with recombinant fowlpox-PSA vaccine is associated with antitumor activity in these patients.
III. Determine the efficacy of prime and boost regimens using recombinant fowlpox-PSA vaccine and recombinant vaccinia-PSA vaccine in these patients.
IV. Compare the PSA-specific T-cell response in patients treated with recombinant fowlpox-PSA vaccine followed by recombinant vaccinia-PSA vaccine vs the same vaccines but in reverse order.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically proven adenocarcinoma of the prostate with evidence of metastatic disease including any of the following:
- •Lymph node positive and prostate-specific antigen (PSA) at least 10 ng/mL
- •Bone scan positive and PSA at least 10 ng/mL
- •Prior radical prostatectomy with rising PSA and PSA at least 2 ng/mL
- •Prior radiotherapy and PSA at least 10 ng/mL
- •Prior cryosurgery and PSA at least 10 ng/mL
- •PSA criteria does not apply to patients who are assigned to group B of this study and were previously treated on vaccine trial DFCI-96079
- •No symptomatic metastatic disease (no bony pain)
- •Complete HLA typing required
- •Performance status - ECOG 0 or 1
- •WBC greater than 2,000/mm^3
- •Platelet count greater than 100,000/mm^3
- •Bilirubin less than 2.0 mg/dL
- •SGPT less than 4 times upper limit of normal
- •Creatinine less than 4.0 mg/dL
- •No altered immune function such as eczema
- •No autoimmune diseases such as the following:
- •Autoimmune neutropenia, thrombocytopenia, or hemolytic anemia
- •Systemic lupus erythematosus, Sjögren's syndrome, or scleroderma
- •Myasthenia gravis
- •Goodpasture's syndrome
- •Addison's disease, Hashimoto's thyroiditis, or active Graves' disease
- •HIV negative
- •No allergy or untoward reaction to prior vaccinia (smallpox) vaccination
- •No hypersensitivity to eggs
- •No prior or concurrent extensive eczema or skin disorders (e.g., extensive psoriasis, burns, impetigo, or disseminated zoster)
- •No other concurrent serious illness
- •No active infection requiring antibiotics until infection has cleared and antibiotics have been stopped for at least 3 days
- •Fertile patients must use effective contraception
- •No close contact or household contact with the following high-risk individuals for at least 2 weeks after each vaccination:
- •Children under age 5
- •Pregnant or nursing women
- •Individuals with prior or concurrent extensive eczema or other eczematoid skin disorders
- •Individuals with other acute, chronic, or exfoliative skin conditions (e.g., atopic dermatitis, burns, impetigo, varicella zoster, severe acne, or other open rashes or wounds)
- •Immunodeficient or immunosuppressed individuals (by disease or therapy) such as those with HIV infection
- •See Disease Characteristics
- •See Endocrine therapy
- •Prior vaccinia (smallpox) immunization required
- •No other concurrent biologic therapy (e.g., interferon or interleukin) for cancer
- •No prior chemotherapy for metastatic disease
- •No concurrent anticancer chemotherapy
- •No prior hormonal therapy for metastatic disease
- •Prior neoadjuvant hormonal therapy followed by prostatectomy or radiotherapy allowed
- •Patients previously treated with recombinant vaccinia-PSA vaccine may have hormonal therapy since discontinuing that treatment (Group B)
- •No concurrent hormonal therapy or steroids
- •See Disease Characteristics
- •See Endocrine therapy
- •No concurrent radiotherapy
- •See Disease Characteristics
- •See Endocrine therapy
- 另有 3 项未显示
排除标准
- 未提供
结局指标
主要结局
PSA response
时间窗: Up to 3 months after the final vaccine dose
PSA response is assessed at 3 successive monthly determinations, starting 28 days after the final vaccine dose.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Vaccine Therapy in Treating HLA-A2 Positive Patients With MelanomaRecurrent MelanomaStage IA MelanomaStage IB MelanomaStage IIA MelanomaStage IIB MelanomaStage IIC MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaNCT00003895National Cancer Institute (NCI)36
已完成
2 期
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Hodgkin LymphomaAdult Non-Hodgkin LymphomaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCytomegaloviral InfectionHematopoietic and Lymphoid Cell NeoplasmHLA-A*0201 Positive Cells PresentAdult Lymphoblastic LymphomaMyeloproliferative NeoplasmChronic Lymphocytic LeukemiaMyelodysplastic SyndromeMyelofibrosisNCT02396134City of Hope Medical Center61
已完成
1 期
Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAARTHIV InfectionsNCT00270205National Institute of Allergy and Infectious Diseases (NIAID)28
终止
1 期
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing CystectomyBladder AdenocarcinomaBladder Squamous Cell CarcinomaBladder Urothelial CarcinomaRecurrent Bladder CarcinomaStage I Bladder CancerStage II Bladder CancerStage III Bladder CancerStage IV Bladder CancerNCT00072137National Cancer Institute (NCI)21
已完成
2 期
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic DermatitisAtopic DermatitisNCT00316602Bavarian Nordic632